Avenue Therapeutics Stock Forecast, Price & News

+0.05 (+3.27 %)
(As of 09/23/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume16,355 shs
Average Volume71,187 shs
Market Capitalization$26.47 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ATXI News and Ratings via Email

Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Avenue Therapeutics logo

About Avenue Therapeutics

Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in New York, NY.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.69 out of 5 stars

Medical Sector

913th out of 1,351 stocks

Pharmaceutical Preparations Industry

450th out of 664 stocks

Analyst Opinion: 3.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Avenue Therapeutics (NASDAQ:ATXI) Frequently Asked Questions

Is Avenue Therapeutics a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Avenue Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATXI, but not buy additional shares or sell existing shares.
View analyst ratings for Avenue Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Avenue Therapeutics?

Wall Street analysts have given Avenue Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Avenue Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Avenue Therapeutics?

Avenue Therapeutics saw a decrease in short interest in August. As of August 13th, there was short interest totaling 265,400 shares, a decrease of 13.8% from the July 29th total of 308,000 shares. Based on an average daily trading volume, of 284,600 shares, the days-to-cover ratio is presently 0.9 days. Currently, 4.0% of the company's stock are short sold.
View Avenue Therapeutics' Short Interest

When is Avenue Therapeutics' next earnings date?

Avenue Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, September 24th 2021.
View our earnings forecast for Avenue Therapeutics

How were Avenue Therapeutics' earnings last quarter?

Avenue Therapeutics, Inc. (NASDAQ:ATXI) issued its earnings results on Sunday, August, 15th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.06).
View Avenue Therapeutics' earnings history

How has Avenue Therapeutics' stock been impacted by Coronavirus?

Avenue Therapeutics' stock was trading at $7.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ATXI shares have decreased by 78.8% and is now trading at $1.58.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ATXI?

1 brokerages have issued 1-year price targets for Avenue Therapeutics' stock. Their forecasts range from $6.00 to $6.00. On average, they expect Avenue Therapeutics' share price to reach $6.00 in the next year. This suggests a possible upside of 279.7% from the stock's current price.
View analysts' price targets for Avenue Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Avenue Therapeutics' key executives?

Avenue Therapeutics' management team includes the following people:
  • Lucy Lu, President, Chief Executive Officer & Director
  • Joseph Vazzano, Chief Financial Officer & Secretary
  • Scott A. Reines, Chief Medical Officer

What other stocks do shareholders of Avenue Therapeutics own?

When did Avenue Therapeutics IPO?

(ATXI) raised $30 million in an IPO on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager.

What is Avenue Therapeutics' stock symbol?

Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."

Who are Avenue Therapeutics' major shareholders?

Avenue Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.69%), National Asset Management Inc. (0.75%), Geode Capital Management LLC (0.48%), Renaissance Technologies LLC (0.47%), Millennium Management LLC (0.44%) and Advisory Services Network LLC (0.21%). Company insiders that own Avenue Therapeutics stock include Joseph Walter Vazzano and Neil Herskowitz.
View institutional ownership trends for Avenue Therapeutics

Which institutional investors are selling Avenue Therapeutics stock?

ATXI stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Northern Trust Corp, Geode Capital Management LLC, National Asset Management Inc., and Parametric Portfolio Associates LLC.
View insider buying and selling activity for Avenue Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Avenue Therapeutics stock?

ATXI stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Millennium Management LLC, Advisory Services Network LLC, Ergoteles LLC, Virtu Financial LLC, Occudo Quantitative Strategies LP, XTX Topco Ltd, and Goldman Sachs Group Inc.. Company insiders that have bought Avenue Therapeutics stock in the last two years include Joseph Walter Vazzano, and Neil Herskowitz.
View insider buying and selling activity for Avenue Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Avenue Therapeutics?

Shares of ATXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avenue Therapeutics' stock price today?

One share of ATXI stock can currently be purchased for approximately $1.58.

How much money does Avenue Therapeutics make?

Avenue Therapeutics has a market capitalization of $26.47 million.

How many employees does Avenue Therapeutics have?

Avenue Therapeutics employs 4 workers across the globe.

What is Avenue Therapeutics' official website?

The official website for Avenue Therapeutics is

Where are Avenue Therapeutics' headquarters?

Avenue Therapeutics is headquartered at 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036.

How can I contact Avenue Therapeutics?

Avenue Therapeutics' mailing address is 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036. The company can be reached via phone at (781) 652-4500 or via email at [email protected].

This page was last updated on 9/24/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.